FAT4 (FAT Atypical Cadherin 4)

NFATc3 was enriched at DREAM target promoters and associated with the DREAM complex, possibly via LIN9, a scaffolding protein of the Multi-Vulva class B (MuvB) core proteins. These findings reveal an unexpected role for NFATc3 in promoting DREAM target gene transactivation and suggest the calcium-NFATc3 axis as a molecular target in LUAD, enriched by DREAM complex activation.

We proposed a non-invasive prediction method based on TEX-related genes, which effectively predicts survival outcomes and therapeutic responses in COAD patients. Additionally, FAT4 was found to regulate proliferative and apoptotic phenotypes in COAD.

Divergent evolutionary patterns highlight species-specific oncogenic routes while underscoring conserved pathways. Comparative primate cancer genomics offers novel insights into cancer evolution, biomarkers, and therapeutic targets.

Integrating multivariate predictive modeling with biological interpretation provides a comprehensive framework for personalized risk stratification and treatment decision-making in EOC. The identified prognostic biomarkers, such as TPM4, SDHD, MUC16, and BCL6, represent potential targets for future studies and therapeutic interventions.

HAS and non-hepatoid AFPGC exhibit a high degree of similarity at both the genomic and transcriptomic levels.

This study comprehensively integrated and analyzed research results on the characteristics of the FAT gene family in lung cancer, focusing on its mutations, signaling pathways, and immunological roles, as well as its clinical significance in terms of prognosis. This study provides theoretical support and references for the development of targeted therapeutic strategies.

The melanomas found in these veterans showed a significantly higher frequency of variants in CDKN2A/B; a significantly lower frequency of variants in ROS1, GRIN2A, KDR, KMT2C (MLL3), KMT2D (MLL2), LRP1B, PTPRT, PTCH1, FAT4, and PREX2; and a significantly higher frequency of tumor mutational burdens exceeding 10 mutations/megabase. The presence of statistically significant differences between the genomic findings from the veterans' melanomas and those of general population melanomas from reference databases suggests that additional research is warranted to corroborate these differences and clarify their etiologic, prognostic, and therapeutic relevance.

The consistency between the actual and predicted event rates was assessed using calibration plots, and validation was performed using bootstrapping resampling. It was demonstrated that the integration of FAT4 mutation and TP53 mutation into the FAT4-TP53-IPI model can enhance the prognostic value of the IPI scoring system.

Collectively, BFT exposure epigenetically modifies the expression of TSGs and impacts migration/invasion potential of breast cancer cells, and treatment with demethylation agent(s) and HDAC inhibitors effectively diminishes the functional impact of BFT.

FAT4 (26%) and TET2 (15%) emerged as important mutated driver genes and potential therapeutic targets for further investigation. We have highlighted distinct differences in driver gene mutations in our cohort of young CRC from sub-Saharan Africa and have identified FAT4 and TET2 as potential drivers that are more common and are potential therapeutic targets.

Western blot experiments and transmission electron microscopy (TEM) results for biological samples revealed that UBE4B inhibits autophagy in GC cells and directly binds to and degrades FAT4 through ubiquitination. These results suggest that UBE4B can inhibit autophagy and promote GC progression by mediating FAT4 ubiquitination and degradation, and our findings provide a new potential therapeutic target for GC management.

These consistent MAE genes were found to interact with both MAE and non-MAE genes, highlighting a well-connected network of MAE genes. Overall, these findings could contribute to the development of effective diagnostic and prognostic models and support efforts in implementing tailored treatment strategies and vaccines for NSCLC.